Article Abstract

Recalcitrant small cell lung cancer: the argument for optimism

Authors: Karen G. Zeman, Christina E. Brzezniak, Corey A. Carter


The US passed the Recalcitrant Cancer Research Act of 2012 to target malignancies with 5-year survival rate less than 50%, to include lung malignancies, with the goal to reduce mortality by fifty percent (1). Small cell lung cancer (SCLC) is the third most common histology of lung cancer accounting for approximately 15% of lung cancer worldwide.